All Updates

All Updates

icon
Filter
Funding
CARGO Therapeutics to raise USD 110 million in private equity funding
Cell & Gene Therapy
May 28, 2024
Last week:
Partnerships
Geographic expansion
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Industry news
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Cell & Gene Therapy

Cell & Gene Therapy

May 28, 2024

CARGO Therapeutics to raise USD 110 million in private equity funding

Funding

  • California-based CAR T-cell therapy company Cargo Therapeutics has entered a securities purchase agreement to raise USD 110 million in a private placement. The round saw participation from several investors, including EcoR1 Capital, Woodline Partners LP, and Saturn V Capital.

  • The company, which debuted on the Nasdaq in November 2023 , intends to use the funds to support the development of its potentially pivotal Phase II study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022). The company aims to use the funds till 2026 to advance IND-enabling studies for CRG-023 and Biologics License Application (BLA) preparations.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.